Literature DB >> 21131550

Modeling the effect of propofol and remifentanil combinations for sedation-analgesia in endoscopic procedures using an Adaptive Neuro Fuzzy Inference System (ANFIS).

P L Gambús1, E W Jensen, M Jospin, X Borrat, G Martínez Pallí, J Fernández-Candil, J F Valencia, X Barba, P Caminal, I F Trocóniz.   

Abstract

BACKGROUND: The increasing demand for anesthetic procedures in the gastrointestinal endoscopy area has not been followed by a similar increase in the methods to provide and control sedation and analgesia for these patients. In this study, we evaluated different combinations of propofol and remifentanil, administered through a target-controlled infusion system, to estimate the optimal concentrations as well as the best way to control the sedative effects induced by the combinations of drugs in patients undergoing ultrasonographic endoscopy.
METHODS: One hundred twenty patients undergoing ultrasonographic endoscopy were randomized to receive, by means of a target-controlled infusion system, a fixed effect-site concentration of either propofol or remifentanil of 8 different possible concentrations, allowing adjustment of the concentrations of the other drug. Predicted effect-site propofol (C(e)pro) and remifentanil (C(e)remi) concentrations, parameters derived from auditory evoked potential, autoregressive auditory evoked potential index (AAI/2) and electroencephalogram (bispectral index [BIS] and index of consciousness [IoC]) signals, as well as categorical scores of sedation (Ramsay Sedation Scale [RSS] score) in the presence or absence of nociceptive stimulation, were collected, recorded, and analyzed using an Adaptive Neuro Fuzzy Inference System. The models described for the relationship between C(e)pro and C(e)remi versus AAI/2, BIS, and IoC were diagnosed for inaccuracy using median absolute performance error (MDAPE) and median root mean squared error (MDRMSE), and for bias using median performance error (MDPE). The models were validated in a prospective group of 68 new patients receiving different combinations of propofol and remifentanil. The predictive ability (P(k)) of AAI/2, BIS, and IoC with respect to the sedation level, RSS score, was also explored.
RESULTS: Data from 110 patients were analyzed in the training group. The resulting estimated models had an MDAPE of 32.87, 12.89, and 8.77; an MDRMSE of 17.01, 12.81, and 9.40; and an MDPE of -1.86, 3.97, and 2.21 for AAI/2, BIS, and IoC, respectively, in the absence of stimulation and similar values under stimulation. P(k) values were 0.82, 0.81, and 0.85 for AAI/2, BIS, and IoC, respectively. The model predicted the prospective validation data with an MDAPE of 34.81, 14.78, and 10.25; an MDRMSE of 16.81, 15.91, and 11.81; an MDPE of -8.37, 5.65, and -1.43; and P(k) values of 0.81, 0.8, and 0.8 for AAI/2, BIS, and IoC, respectively.
CONCLUSION: A model relating C(e)pro and C(e)remi to AAI/2, BIS, and IoC has been developed and prospectively validated. Based on these models, the (C(e)pro, C(e)remi) concentration pairs that provide an RSS score of 4 range from (1.8 μg·mL(-1), 1.5 ng·mL(-1)) to (2.7 μg·mL(-1), 0 ng·mL(-1)). These concentrations are associated with AAI/2 values of 25 to 30, BIS of 71 to 75, and IoC of 72 to 76. The presence of noxious stimulation increases the requirements of C(e)pro and C(e)remi to achieve the same degree of sedative effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21131550     DOI: 10.1213/ANE.0b013e3182025a70

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  9 in total

Review 1.  Monitoring during difficult airway management.

Authors:  Takashi Asai
Journal:  J Anesth       Date:  2013-07-09       Impact factor: 2.078

Review 2.  Pharmacokinetic-pharmacodynamic modelling in anaesthesia.

Authors:  Pedro L Gambús; Iñaki F Trocóniz
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

3.  Comparison of the qCON and qNOX indices for the assessment of unconsciousness level and noxious stimulation response during surgery.

Authors:  Umberto Melia; Eva Gabarron; Mercé Agustí; Nuria Souto; Patricia Pineda; Joan Fontanet; Montserrat Vallverdu; Erik Weber Jensen; Pedro Gambus
Journal:  J Clin Monit Comput       Date:  2016-10-20       Impact factor: 2.502

4.  Individualizing propofol dosage: a multivariate linear model approach.

Authors:  Conceição Rocha; Teresa Mendonça; Maria Eduarda Silva; Pedro Gambús
Journal:  J Clin Monit Comput       Date:  2013-09-27       Impact factor: 2.502

5.  Evaluation of SLOG/TCI-III pediatric system on target control infusion of propofol.

Authors:  Wan-hua Yang; Hong-bin Gu; Bing Chen; Juan Li; Qiu-wei Fan; Yong-fang Yuan; Xiangdong Wang
Journal:  J Transl Med       Date:  2011-11-01       Impact factor: 5.531

6.  Prediction of Nociceptive Responses during Sedation by Linear and Non-Linear Measures of EEG Signals in High Frequencies.

Authors:  Umberto Melia; Montserrat Vallverdú; Xavier Borrat; Jose Fernando Valencia; Mathieu Jospin; Erik Weber Jensen; Pedro Gambus; Pere Caminal
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

7.  Effects of small-dose remifentanil combined with index of consciousness monitoring on gastroscopic polypectomy: a prospective, randomized, single-blinded trial.

Authors:  Minqiang Liu; Hongyan Wu; Danling Yang; Fengxian Li; Zhichao Li; Song Wang; Renliang He
Journal:  Trials       Date:  2018-07-18       Impact factor: 2.279

8.  Evaluating the effect of an artificial intelligence system on the anesthesia quality control during gastrointestinal endoscopy with sedation: a randomized controlled trial.

Authors:  Cheng Xu; Yijie Zhu; Lianlian Wu; Shaoqing Lei; Zhongyuan Xia; Honggang Yu; Jun Liu; Fang Zhou; Qiutang Xiong; Shanshan Wang; Shanshan Cui; Xu Huang; Anning Yin; Tingting Xu
Journal:  BMC Anesthesiol       Date:  2022-10-07       Impact factor: 2.376

9.  Effects of indexes of consciousness (IoC1 and IoC2) monitoring on remifentanil dosage in modified radical mastectomy: a randomized trial.

Authors:  Guisheng Wu; Lei Zhang; Xuxiang Wang; Ailan Yu; Zongwang Zhang; Jingui Yu
Journal:  Trials       Date:  2016-03-29       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.